

**pan-Canadian Pharmaceutical
Alliance Corporation
Financial Statements
For the Period Ended March 31, 2023**

pan-Canadian Pharmaceutical Alliance Corporation
Financial Statements
For the Period Ended March 31, 2023

Contents

| | |
|---|-------|
| Independent Auditor's Report | 1 - 2 |
| Financial Statements | |
| Statement of Financial Position | 3 |
| Statement of Operations and Changes in Net Assets | 4 |
| Statement of Cash Flows | 5 |
| Notes to Financial Statements | 6 - 9 |



Tel: 604 932 3799
Fax: 604 932 3764
whistler@bdo.ca
www.bdo.ca

BDO Canada LLP
202 - 1200 Alpha Lake Road
Whistler, BC V8E 0H6

Independent Auditor's Report

To the board of pan-Canadian Pharmaceutical Alliance Corporation

Opinion

We have audited the financial statements of pan-Canadian Pharmaceutical Alliance Corporation (the "Entity"), which comprise the statement of financial position as at March 31, 2023, the statements of operations and changes in net assets and cash flows for the period then ended, and notes to the financial statements, including a summary of significant accounting policies.

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of the Entity as at March 31, 2023, and its financial performance and cash flows for the period then ended in accordance with Canadian accounting standards for not-for-profit organizations.

Basis for Opinion

We conducted our audit in accordance with Canadian generally accepted auditing standards. Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Statements* section of our report. We are independent of the Entity in accordance with the ethical requirements that are relevant to our audit of the financial statements in Canada, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Responsibilities of Management and Those Charged with Governance for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with Canadian accounting standards for not-for-profit organizations, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Entity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Entity or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Entity's financial reporting process.



Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Canadian generally accepted auditing standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with Canadian generally accepted auditing standards, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Entity's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Entity's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Entity to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

BDO Canada LLP

Chartered Professional Accountants

Whistler, British Columbia
June 26, 2023

pan-Canadian Pharmaceutical Alliance Corporation
Statement of Financial Position

March 31 **2023**

Assets

Current

| | |
|------------------------|---------------------|
| Cash (Note 2) | \$18,464,522 |
| Term deposits (Note 3) | 125,000 |
| Prepaid expenses | <u>10,024</u> |
| | <u>\$18,599,546</u> |

Liabilities and Net Assets


Current


| | |
|--|-------------------|
| Accounts payable and accrued liabilities | \$ 100,607 |
| Deferred contributions (Note 4) | <u>18,498,939</u> |
| | <u>18,599,546</u> |

Net Assets

-
\$18,599,546

On behalf of the Board:

DocuSigned by:

 _____ Director
E1F6913310C943B...

DocuSigned by:

 _____ Director
18A76A0912124CF...

pan-Canadian Pharmaceutical Alliance Corporation
Statement of Operations and Changes in Net Assets

For the period ended March 31

2023

| | |
|-------------------------------------|-------------------|
| Revenue (Note 4) | <u>\$ 301,061</u> |
| Expenses | |
| Interest and bank charges | 113 |
| Insurance | 2,006 |
| Office expenses | 61,463 |
| Professional fees | 101,290 |
| Sub-contracts | 50,212 |
| Travel expenses | 3,136 |
| Utilities | 5,045 |
| Other operating expenses | <u>77,796</u> |
| | <u>301,061</u> |
| Excess of revenues over expenses | \$ - |
| Net Assets, beginning of the period | <u>-</u> |
| Net Assets, end of period | <u>\$ -</u> |

The accompanying notes are an integral part of these financial statements.

pan-Canadian Pharmaceutical Alliance Corporation
Statement of Cash Flows

| For the period ended March 31 | 2023 |
|---|----------------------------|
| Cash flows from operating activities | |
| Excess of revenues over expenses | \$ <u>-</u> |
| Changes in non-cash working capital: | |
| Prepaid expenses | (10,024) |
| Accounts payable and accrued liabilities | 100,607 |
| Deferred contributions | <u>(301,061)</u> |
| | <u>(210,478)</u> |
| Cash flows from investing activities | |
| Purchase of investment | <u>(125,000)</u> |
| Cash flows from financing activities | |
| Receipt of deferred contributions | <u>18,800,000</u> |
| Net increase in cash | 18,464,522 |
| Cash, beginning of the period | <u>-</u> |
| Cash, end of the period | <u>\$18,464,522</u> |

The accompanying notes are an integral part of these financial statements.

pan-Canadian Pharmaceutical Alliance Corporation

Notes to Financial Statements

March 31, 2023

1. Significant Accounting Policies

| | |
|---|--|
| Nature and Purpose of Organization | <p>The pan-Canadian Pharmaceutical Alliance Corporation (the "Corporation") is a non-profit organization incorporated without share capital under the Canada Not-for-profit Corporations Act. The Corporation is exempt from income tax under Section 149 of the Income Tax Act.</p> <p>The purposes of the Corporation is:</p> <ul style="list-style-type: none">(a) to provide value to the provincial, territorial and federal health care systems of Canada and to improve patient care by conducting negotiations for pharmaceuticals and related products and services to:<ul style="list-style-type: none">(i) increase access to clinically and cost effective drug treatment options;(ii) improve consistency of drug funding decisions;(iii) achieve consistent and lower drug costs; and(iv) reduce duplication of effort and improve use of resources; <p>and</p> <ul style="list-style-type: none">(b) to do all such other lawful things as may be incidental and ancillary to carrying out the foregoing purposes. <p>The Corporation was incorporated on October 19, 2022 and is currently in that startup stage of operations. The Corporation is expected to grow and reach the full scale of its operations throughout the 2023/2024 fiscal year.</p> <p>The Corporation's members are comprised of the provincial, territorial and federal governments of Canada.</p> |
| Basis of Accounting | <p>These financial statements have been prepared using Canadian accounting standards for not-for-profit organizations ("ASNPO").</p> |
| Revenue Recognition | <p>The Corporation follows the deferral method of accounting for contributions.</p> <p>Externally restricted contributions are deferred recognized as revenue in the period in which the related expenses are incurred or restrictions have been met. Unrestricted contributions are recognized as revenue when received or receivable if the amount to be received can be reasonably estimated and collection is reasonably assured.</p> |

pan-Canadian Pharmaceutical Alliance Corporation

Notes to Financial Statements

March 31, 2023

1. Significant Accounting Policies (continued)

Financial Instruments The Corporation's financial instruments consist of cash, short term investments, and accounts payable and accrued liabilities. Financial assets are tested for impairment when changes in circumstances indicate an asset could be impaired. The Corporation initially measures its financial instruments at fair value and subsequently at amortized cost using the effective interest rate method, less any provision for impairment.

Use of Estimates The preparation of financial statements using ASNPO requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Areas requiring management to exercise judgement on the determination of estimates includes the completeness of accounts payable and accrued liabilities. Actual results could differ from management's best estimates made in the preparation of these financial statements and may have an impact on future periods.

pan-Canadian Pharmaceutical Alliance Corporation Notes to Financial Statements

March 31, 2023

2. Cash

The Corporation's bank accounts are held at one Canadian chartered bank, earning interest at the current prevailing rate. All of the cash held by the Corporation is restricted in use as stipulated by the contributions provided by funders (Note 4).

3. Investments

The Corporation holds a non-redeemable Guaranteed Investment Certificate (GIC) which matures January 8, 2024, earning interest at 4.65% per annum.

4. Deferred Contributions

During the year, the Corporation received \$18,800,000 from a predecessor organization which has been contributed to the Corporation toward the continuation of these services by the Corporation on a go forward basis commencing October 19, 2022 when the Corporation was incorporated. This funding represents contributions from the Government of Canada, in lieu of financial contributions from provincial and territorial members, and is externally restricted to fund the Corporation's annual operating budget and to support initiatives of the Corporation. These contributions are to be utilized by March 31, 2027, with the use of any unspent funds to be determined by the Conference of the Provincial and Territorial Deputy Ministers of Health.

Changes in the deferred contributions balance are as follows:

| | <u>2023</u> |
|---|---------------------|
| Balance, beginning of year | \$ - |
| Contributions received in the year and deferred | 18,800,000 |
| Recognized as revenue | <u>(301,061)</u> |
| Balance, end of year | <u>\$18,498,939</u> |

pan-Canadian Pharmaceutical Alliance Corporation

Notes to Financial Statements

March 31, 2023

5. Financial Instruments

Credit risk

Credit risk is the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation. The Corporation is exposed to credit risk resulting from the possibility that a counterparty to a financial instrument defaults on their financial obligations; if there is a concentration of transactions carried out with the same counterparty; or of financial obligations which have similar economic characteristics such that they could be similarly affected by changes in economic conditions. The Corporation is exposed to credit risk arising from all of its bank accounts being held at one financial institution of which only eligible deposits are only insured up to \$100,000.

Liquidity risk

Liquidity risk is the risk that the Corporation will encounter difficulty in meeting its obligations associated with financial liabilities. Liquidity risk includes the risk that, as a result of operational liquidity requirements, the Corporation will not have sufficient funds to settle a transaction on the due date; will be forced to sell financial assets at a value, which is less than what they are worth; or may be unable to settle or recover a financial asset. Liquidity risk arises from accounts payable and accrued liabilities. The Corporation manages its liquidity by matching expenditures to approved funding and by carrying sufficient cash reserves to meet its current obligations.

It is management's opinion that the Corporation is not exposed to significant currency or interest rate risk arising from financial instruments.

6. Economic Dependence

The Corporation's operations are funded entirely by restricted contributions provided by the Government of Canada (Note 4). As a result, the Corporation is economically dependent on the Government of Canada to carry out its mandate. If contributions provided by the Government of Canada, as described in Note 4, are exhausted prior to March 31, 2027; the Corporation has the option to raise contributions directly from the members of the Corporation.
